Clinical trial of potential vaccine for coeliac disease
22 Mar 2018
USC’s Clinical Trials Centre will launch a clinical trial of a new vaccine on 23 March that aims to improve the lives of those with coeliac disease by ‘switching off’ the immune response to gluten.
Coeliac disease is a serious chronic medical condition in which the ingestion of gluten, even in small amounts, leads to an immune response that causes damage to the small intestine.
Sufferers struggle with various gastrointestinal symptoms and, if untreated, face potentially serious complications. Currently, the only way to manage the disease is by the strict avoidance of gluten in the diet.
He said the trial would be conducted alongside gastroenterologist Dr James Daveson at the Clinical Trial Centre on Sippy Downs Drive, Sippy Downs.
Dr Daveson said a gluten-free diet was exceptionally demanding for patients, expensive and difficult to maintain as gluten was used extensively in modern food production.
“There is a real unmet need for therapies other than the gluten-free diet for some people with coeliac disease,” he said. “This is a very exciting potential new therapy that has been undergoing clinical trials for several years now.”
Dr Daveson said the investigational vaccine might potentially restore gluten tolerance in coeliac disease sufferers.
Adults between the ages of 18 and 70 can take part in this trial if they have medically diagnosed coeliac disease and have been following a strict gluten-free diet for 12 months or more.
Those who meet the criteria and are enrolled in the study will be compensated for their time. Patients interested in participating can go to www.joinourtrials.com or phone (07) 5456 3797.
- Janelle Kirkland
Study to assess patient confidence in clinical trials9 Jan
USC Clinical Trials will this year develop a new way to evaluate and improve the experience of medical trial participants, thanks to a new grant.
Clinical trial of medication that targets triglycerides1 Dec 2019
USC Clinical Trials will participate in a study of an investigational medication for the treatment of dyslipidaemia – a condition that involves abnormally elevated levels of lipids (fats) in the blood.
Clinical trials commitment earns industry award4 Nov 2019
The Director of USC Clinical Trials, Lucas Litewka, has been recognised nationally for his significant contribution to the medical technology and pharmaceuticals (MTP) sector.